It is a time for MPLT - 40% POTENTIAL PROFIT - 18.50 USDOn the 4H chart of MapLight Therapeutics, the price is sitting in a heavily oversold zone after an extended downward move, but the recent candles indicate a potential slowdown in selling pressure. The price is reacting near a local bottom, suggesting that the market may be forming a base for a possi
MapLight Therapeutics, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−77.58 M USD
0.00 USD
20.43 M
About MapLight Therapeutics, Inc.
Sector
Industry
CEO
Christopher A. Kroeger
Website
Headquarters
Redwood City
Founded
2018
IPO date
Oct 27, 2025
IPO offer price
17.00 USD
Identifiers
3
ISIN US56565P1030
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
Related stocks
MPLT: Is the IPO working according to a scenarioAfter the IPO, the stock is forming a falling wedge — a classic post-listing accumulation pattern. Price is consolidating between the 15.03 support level and the accumulation zone. We see a trendline breakout attempt and price trying to hold above. The key resistance is 19.01, aligning with the prev
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MPLT is 17.69 USD — it has decreased by −4.79% in the past 24 hours. Watch MapLight Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MapLight Therapeutics, Inc. stocks are traded under the ticker MPLT.
MPLT stock has fallen by −5.95% compared to the previous week, the month change is a −1.17% fall, over the last year MapLight Therapeutics, Inc. has showed a −6.89% decrease.
We've gathered analysts' opinions on MapLight Therapeutics, Inc. future price: according to them, MPLT price has a max estimate of 34.00 USD and a min estimate of 28.00 USD. Watch MPLT chart and read a more detailed MapLight Therapeutics, Inc. stock forecast: see what analysts think of MapLight Therapeutics, Inc. and suggest that you do with its stocks.
MPLT reached its all-time high on Dec 15, 2025 with the price of 21.55 USD, and its all-time low was 12.24 USD and was reached on Nov 26, 2025. View more price dynamics on MPLT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MPLT stock is 6.14% volatile and has beta coefficient of 0.25. Track MapLight Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is MapLight Therapeutics, Inc. there?
Today MapLight Therapeutics, Inc. has the market capitalization of 802.65 M, it has increased by 12.98% over the last week.
Yes, you can track MapLight Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
MapLight Therapeutics, Inc. is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
MPLT earnings for the last quarter are −37.18 USD per share, whereas the estimation was −1.73 USD resulting in a −2.06 K% surprise. The estimated earnings for the next quarter are −0.99 USD per share. See more details about MapLight Therapeutics, Inc. earnings.
MapLight Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MPLT net income for the last quarter is −29.42 M USD, while the quarter before that showed −29.85 M USD of net income which accounts for 1.43% change. Track more MapLight Therapeutics, Inc. financial stats to get the full picture.
No, MPLT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MPLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MapLight Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.

